ALX Oncology (NASDAQ:ALXO) Rating Reiterated by Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXOGet Free Report)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports.

A number of other analysts have also weighed in on ALXO. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of ALX Oncology in a research report on Wednesday, April 10th. Stifel Nicolaus restated a “hold” rating and issued a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.83.

Check Out Our Latest Analysis on ALXO

ALX Oncology Stock Performance

Shares of ALXO traded down $0.64 during mid-day trading on Wednesday, hitting $11.92. 58,066 shares of the company’s stock were exchanged, compared to its average volume of 452,694. ALX Oncology has a 52 week low of $3.94 and a 52 week high of $17.83. The stock’s 50-day simple moving average is $14.06 and its 200-day simple moving average is $13.47. The firm has a market cap of $621.03 million, a price-to-earnings ratio of -3.22 and a beta of 1.30. The company has a quick ratio of 5.21, a current ratio of 5.21 and a debt-to-equity ratio of 0.06.

ALX Oncology (NASDAQ:ALXOGet Free Report) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). On average, equities research analysts expect that ALX Oncology will post -2.89 EPS for the current year.

Insider Activity

In other news, insider Sophia Randolph sold 12,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the completion of the transaction, the insider now owns 330,349 shares of the company’s stock, valued at $5,265,763.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Sophia Randolph sold 12,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the completion of the transaction, the insider now owns 330,349 shares of the company’s stock, valued at $5,265,763.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jason Lettmann bought 4,400 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were purchased at an average cost of $11.31 per share, with a total value of $49,764.00. Following the purchase, the chief executive officer now directly owns 171,620 shares of the company’s stock, valued at $1,941,022.20. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 102,000 shares of company stock valued at $1,442,680. Insiders own 33.40% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

Hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System increased its stake in ALX Oncology by 413.8% in the first quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock valued at $254,000 after purchasing an additional 18,360 shares in the last quarter. Redmile Group LLC increased its stake in ALX Oncology by 18.2% in the first quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock valued at $48,241,000 after purchasing an additional 667,245 shares in the last quarter. EntryPoint Capital LLC bought a new stake in ALX Oncology in the first quarter valued at $32,000. CANADA LIFE ASSURANCE Co bought a new stake in ALX Oncology in the first quarter valued at $27,000. Finally, Vanguard Group Inc. increased its stake in ALX Oncology by 4.3% in the first quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock valued at $17,466,000 after purchasing an additional 64,055 shares in the last quarter. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

(Get Free Report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Recommended Stories

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.